Sun Pharma reports Q4 net loss at ₹2,277 cr
The Hindu
Sun Pharma’s shares 1.75% down at ₹888.10 apiece on the BSE
Sun Pharmaceutical Industries on Monday said its consolidated net loss stood at ₹2,277 crore for the fourth quarter ended March 2022, mainly on account of a one-time exceptional loss.
The Mumbai-based drug major had reported a net profit of ₹894 crore in the January-March period of 2020-21.
Consolidated sales from operations stood at ₹9,386 crore in the fourth quarter.
The company had reported sales from operations at ₹8,464 crore in the year-ago period.
During the period under review, the company said it incurred a one-time cost of ₹56.35 crore for restructuring operations in certain countries.
Total loss cited as an exceptional item during the fourth quarter, stood at ₹3,936 crore.
For the year ended March 2022, the company reported a consolidated net profit of ₹3,273 crore. The same stood at ₹2,904 crore in FY21.













